Recent Company News

• 08:00 AM ET Aug 27, 2025
  

  Evaxion to present at several conferences during the second half of 2025

• 07:34 AM ET Aug 14, 2025
  

  Evaxion Biotech reports Q2 EPS ($0.02) vs FactSet ($0.58) [2 est, ($0.66)-(0.50)] ($3.04, 0.00)

• 07:30 AM ET Aug 14, 2025
  

  Evaxion announces business update and second quarter 2025 financial results

• 08:00 AM ET Aug 11, 2025
  

  Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

• 03:52 PM ET Jul 29, 2025
  

  Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments

• 09:03 AM ET Jul 25, 2025
  

  Evaxion to present two-year clinical efficacy data of EVX-01 at the ESMO Congress 2025 ($2.71, 0.00)

• 09:00 AM ET Jul 25, 2025
  

  Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

• 08:02 AM ET Jul 11, 2025
  

  Evaxion Biotech finalizes agreement with EIB to convert debt into equity ($2.58, 0.00)

• 08:33 AM ET Jul 01, 2025
  

  Evaxion announces changes to executive management ($2.45, 0.00)

• 08:03 AM ET Jun 25, 2025
  

  Evaxion Biotech expands R&D pipeline with new vaccine program EVX-B4 targeting Group A Streptococcus ($2.45, 0.00)